Figure 3From: Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patientsa&b: Number of metabolic risk factors present in metabolic syndrome patients with Irbesartan alone (Figure 3a) or in combination with HCTZ (Figure 3b). p < 0.0001 for the comparison of 3-month and 9-month to baseline; statistical test applied: Chi2-testBack to article page